Conflicts of Interest:
Author K. Walkovich discloses the following potential conflicts of interest: she is the local principal investigator for the Mavorixafor trial (sponsored by X4 Pharmaceuticals); she is a member of the steering committee for Sobi; and she is on the advisory board for Sobi, Pharming, AstraZeneca, Horizon, and X4 Pharmaceuticals. None of these are relevant to this study however. The remaining authors have no relevant conflicts of interest to disclose.
References :
1. Allen CE, Merad M, McClain KL. Langerhans-Cell Histiocytosis. N Engl J Med . Aug 30 2018;379(9):856-868. doi:10.1056/NEJMra1607548
2. Gadner H, Minkov M, Grois N, et al. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. Blood . Jun 20 2013;121(25):5006-14. doi:10.1182/blood-2012-09-455774
3. Donadieu J, Bernard F, van Noesel M, et al. Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study. Blood . Sep 17 2015;126(12):1415-23. doi:10.1182/blood-2015-03-635151
4. Eckstein O. Randomization of cytarabine monotherapy versus standard-of-care vinblastine/prednisone for frontline treatment of Langerhans Cell Histiocytosis (TXCH LCH0115). ClinicalTrials.gov identifier: NCT02670707. Updated June 12, 2023. Accessed July 7, 2023. https://www.clinicaltrials.gov/study/NCT02670707
5. Rabin RC. Faced with a drug shortfall, doctors scramble to treat children with cancer. New York Times . October 14, 2019. Accessed July 7, 2023. https://www.nytimes.com/2019/10/14/health/cancer-drug-shortage.html
6. McBride A, Hudson-DiSalle S, Pilz J, et al. National Survey on the Effect of Oncology Drug Shortages in Clinical Practice: A Hematology Oncology Pharmacy Association Survey. JCO Oncol Pract . Aug 2022;18(8):e1289-e1296. doi:10.1200/OP.21.00883
7. Arem H, Moses J, Nekhlyudov L, et al. Oncology provider experiences during the COVID-19 pandemic. PLoS One . 2022;17(7):e0270651. doi:10.1371/journal.pone.0270651
8. Maloney KW, Devidas M, Wang C, et al. Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Children’s Oncology Group Trial AALL0331. J Clin Oncol . Feb 20 2020;38(6):602-612. doi:10.1200/JCO.19.01086
9. Angiolillo AL, Schore RJ, Kairalla JA, et al. Excellent Outcomes With Reduced Frequency of Vincristine and Dexamethasone Pulses in Standard-Risk B-Lymphoblastic Leukemia: Results From Children’s Oncology Group AALL0932. J Clin Oncol . May 1 2021;39(13):1437-1447. doi:10.1200/JCO.20.00494
10. Eckstein OS, Bernhardt MB, Hood CG, Karri V, Kralik SF, McClain KL. Treatment of Langerhans cell histiocytosis with subcutaneous cytarabine.Pediatr Hematol Oncol . Jan 10 2023:1-9. doi:10.1080/08880018.2022.2137609
11. Liliemark JO, Paul CY, Gahrton CG, Peterson CO. Pharmacokinetics of 1-beta-D-arabinofuranosylcytosine 5’-triphosphate in leukemic cells after intravenous and subcutaneous administration of 1-beta-D-arabinofuranosylcytosine. Cancer Res . May 1985;45(5):2373-5.
12. North American Consortium for Histiocytosis. LCH-IV, international collaborative treatment protocol for children and adolescents with Langerhans Cell Histiocytosis. ClinicalTrials.gov identifier: NCT02205762. Updated March 23, 2023. Accessed July 7, 2023. https://www.clinicaltrials.gov/study/NCT02205762